|Related Categories||Androgen, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience,|
|Gene Information||human ... AR(367)|
Nilutamide is an antiandrogen used in the treatment of prostate cancer.
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. N8534.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.
Certificate of Analysis
Certificate of Origin
|Precautionary statements||P201-P301 + P310-P308 + P313|
|Personal Protective Equipment||Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges|
|Hazard Codes (Europe)||T|
|Risk Statements (Europe)||60-25|
|Safety Statements (Europe)||36/37/39-45|
|RIDADR||UN 2811 6.1 / PGIII|
Intracellular receptors (IRs) are a class of ligand-dependent transcription factors that include receptors for both steroid and non-steroid hormones. Upon binding their cognate hormone, these recepto...
Keywords: Anti-inflammatory agents, Apoptosis, Atomic absorption spectroscopy, Cancer, Cardiovascular, Cell proliferation, Diseases, Diuretics, Gene expression, Hormones, Infrared spectroscopy, Ligands, Metabolism, Metabolites, Transcription, Transduction
Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. Yu J, Akishita M, Eto M, et al. Endocrinology 151(4), 1822-8, (2010)
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Choo R, Danjoux C, Gardner S, et al. Int. J. Radiat. Oncol. Biol. Phys. 75(4), 983-9, (2009)
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Choo R, Danjoux C, Gardner S, et al. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 407-12, (2009)
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Madan RA, Gulley JL, Schlom J, et al. Clin. Cancer Res. 14(14), 4526-31, (2008)
Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide. Payen O, Top S, Vessières A, et al. J. Med. Chem. 51(6), 1791-9, (2008)
Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Langenhuijsen JF, van Lin EN, Hoffmann AL, et al. Urol. Oncol. 29(1), 52-7, (2011)
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Raina R, Pahalajani G, Agarwal A, et al. Asian J. Androl. 9(2), 253-8, (2007)
Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor. Yu J, Eto M, Akishita M, et al. Biochem. Biophys. Res. Commun. 353(3), 764-9, (2007)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?